isoforms. Its lead investigational program, RB042, is an inhaled splice-switching oligonucleotide that modulates the Receptor for Advanced Glycation End-products pathway for indications such as chronic obstructive pulmonary disease and other severe respiratory illnesses. Atisama’s broader pipeline explores applications of its splice-switching platform in additional respiratory conditions including neutrophilic asthma and idiopathic pulmonary fibrosis, as well as non-respiratory indications in kidney, liver and central nervous system diseases. The company collaborates with research institutions to advance these programs through preclinical and clinical development.